The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC). This study aimed to assess whether the presence of targetable driver mutations affects the efficacy of the combination of immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Po-Lan, Chen, Jung-Yueh, Chu, Chang-Yao, Chen, Yi-Lin, Chen, Wan-Li, Lin, Kuan-Yu, Ho, Chung-Liang, Tsai, Jeng-Shiuan, Yang, Szu-Chun, Chen, Chian-Wei, Wu, Yi-Lin, Tseng, Yau-Lin, Chang, Chao-Chun, Yen, Yi-Ting, Lin, Chia-Ying, Lin, Chien-Chung, Su, Wu-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885645/
https://www.ncbi.nlm.nih.gov/pubmed/35228655
http://dx.doi.org/10.1038/s41598-022-07423-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885645/
https://www.ncbi.nlm.nih.gov/pubmed/35228655
http://dx.doi.org/10.1038/s41598-022-07423-w

Ejemplares similares